Qinhao Pharma Completes Over 300 Million Yuan Crossover Round Financing to Accelerate Sustained Innovation

Stock News01-13

On January 13, Qinhao Pharmaceutical, a research and development enterprise dedicated to leveraging its combinatorial technology platform to develop a new generation of global anti-tumor small molecule drugs, announced the completion of a Crossover round financing exceeding 300 million RMB. This funding round was led by Shenzhen Green Pine Capital Partners, with participation from several institutions including Linzhuo Investment, YuanSheng Capital, Guangzhou Industrial Investment, VIVATEC, Mint Fund, and Guoju Investment. As an innovation-driven Biotech company, Qinhao Pharmaceutical has consistently focused on developing globally leading targeted anti-tumor small molecule therapeutics. The company has established a drug development philosophy centered on "AI/Biology-Driven Smart Design," deeply integrating computational chemistry, artificial intelligence, and internal experimental platforms to form an efficient R&D system characterized by "data-driven, rapid iteration," comprehensively empowering the entire process from drug discovery to clinical development. The company has built a differentiated pipeline covering the Ras signaling pathway and the field of synthetic lethality, advancing several globally leading projects into clinical stages, demonstrating its capacity for continuous innovation and aiming to provide internationally competitive solutions for the precise and combined treatment of refractory tumors. Owing to its platform innovation strength and pipeline potential, Qinhao Pharmaceutical has successively received honors such as the "Gusu Major Innovation Team" and the "Jiangsu Provincial Major Special Project," and has participated in the "National Major Science and Technology Project for Innovative Drug Research and Development," with its technical path and innovation value gaining recognition from multiple parties. The completion of this financing round will further accelerate the company's R&D progress and strategic layout. Moving forward, Qinhao Pharmaceutical will leverage its AI-empowered efficient innovation system, focus on unmet clinical needs, collaborate with industry, academia, and research sectors, and continue to advance the development of innovative drugs with global competitiveness, aiming to deliver breakthrough treatment options for patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment